553 related articles for article (PubMed ID: 34709727)
1. SARS-CoV-2-host proteome interactions for antiviral drug discovery.
Liu X; Huuskonen S; Laitinen T; Redchuk T; Bogacheva M; Salokas K; Pöhner I; Öhman T; Tonduru AK; Hassinen A; Gawriyski L; Keskitalo S; Vartiainen MK; Pietiäinen V; Poso A; Varjosalo M
Mol Syst Biol; 2021 Nov; 17(11):e10396. PubMed ID: 34709727
[TBL] [Abstract][Full Text] [Related]
2. Mapping the SARS-CoV-2-Host Protein-Protein Interactome by Affinity Purification Mass Spectrometry and Proximity-Dependent Biotin Labeling: A Rational and Straightforward Route to Discover Host-Directed Anti-SARS-CoV-2 Therapeutics.
Terracciano R; Preianò M; Fregola A; Pelaia C; Montalcini T; Savino R
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430309
[TBL] [Abstract][Full Text] [Related]
3. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
[TBL] [Abstract][Full Text] [Related]
4. Open Science Resources for the Mass Spectrometry-Based Analysis of SARS-CoV-2.
Bittremieux W; Adams C; Laukens K; Dorrestein PC; Bandeira N
J Proteome Res; 2021 Mar; 20(3):1464-1475. PubMed ID: 33605735
[TBL] [Abstract][Full Text] [Related]
5. Cellular host factors for SARS-CoV-2 infection.
Baggen J; Vanstreels E; Jansen S; Daelemans D
Nat Microbiol; 2021 Oct; 6(10):1219-1232. PubMed ID: 34471255
[TBL] [Abstract][Full Text] [Related]
6. The global succinylation of SARS-CoV-2-infected host cells reveals drug targets.
Liu Q; Wang H; Zhang H; Sui L; Li L; Xu W; Du S; Hao P; Jiang Y; Chen J; Qu X; Tian M; Zhao Y; Guo X; Wang X; Song W; Song G; Wei Z; Hou Z; Wang G; Sun M; Li X; Lu H; Zhuang X; Jin N; Zhao Y; Li C; Liao M
Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2123065119. PubMed ID: 35858407
[TBL] [Abstract][Full Text] [Related]
7. A systems-based method to repurpose marketed therapeutics for antiviral use: a SARS-CoV-2 case study.
Wang M; Withers JB; Ricchiuto P; Voitalov I; McAnally M; Sanchez HN; Saleh A; Akmaev VR; Ghiassian SD
Life Sci Alliance; 2021 May; 4(5):. PubMed ID: 33593923
[TBL] [Abstract][Full Text] [Related]
8. Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs.
More SA; Patil AS; Sakle NS; Mokale SN
Virology; 2021 Mar; 555():10-18. PubMed ID: 33421743
[TBL] [Abstract][Full Text] [Related]
9. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions.
Bakowski MA; Beutler N; Wolff KC; Kirkpatrick MG; Chen E; Nguyen TH; Riva L; Shaabani N; Parren M; Ricketts J; Gupta AK; Pan K; Kuo P; Fuller M; Garcia E; Teijaro JR; Yang L; Sahoo D; Chi V; Huang E; Vargas N; Roberts AJ; Das S; Ghosh P; Woods AK; Joseph SB; Hull MV; Schultz PG; Burton DR; Chatterjee AK; McNamara CW; Rogers TF
Nat Commun; 2021 Jun; 12(1):3309. PubMed ID: 34083527
[TBL] [Abstract][Full Text] [Related]
10. Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19.
van de Leemput J; Han Z
Mol Cell Biol; 2021 Aug; 41(9):e0018521. PubMed ID: 34124934
[TBL] [Abstract][Full Text] [Related]
11. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19.
Senapati S; Banerjee P; Bhagavatula S; Kushwaha PP; Kumar S
J Genet; 2021; 100(1):. PubMed ID: 33707363
[TBL] [Abstract][Full Text] [Related]
12. Understanding Severe Acute Respiratory Syndrome Coronavirus 2 Replication to Design Efficient Drug Combination Therapies.
Ortega JT; Zambrano JL; Jastrzebska B; Liprandi F; Rangel HR; Pujol FH
Intervirology; 2020; 63(1-6):2-9. PubMed ID: 33099545
[TBL] [Abstract][Full Text] [Related]
13. Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV.
Stukalov A; Girault V; Grass V; Karayel O; Bergant V; Urban C; Haas DA; Huang Y; Oubraham L; Wang A; Hamad MS; Piras A; Hansen FM; Tanzer MC; Paron I; Zinzula L; Engleitner T; Reinecke M; Lavacca TM; Ehmann R; Wölfel R; Jores J; Kuster B; Protzer U; Rad R; Ziebuhr J; Thiel V; Scaturro P; Mann M; Pichlmair A
Nature; 2021 Jun; 594(7862):246-252. PubMed ID: 33845483
[TBL] [Abstract][Full Text] [Related]
14. Genome-scale metabolic modeling reveals SARS-CoV-2-induced metabolic changes and antiviral targets.
Cheng K; Martin-Sancho L; Pal LR; Pu Y; Riva L; Yin X; Sinha S; Nair NU; Chanda SK; Ruppin E
Mol Syst Biol; 2021 Nov; 17(11):e10260. PubMed ID: 34709707
[TBL] [Abstract][Full Text] [Related]
15. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
16. Effective inhibition of coronavirus replication by
Xu H; Li J; Song S; Xiao Z; Chen X; Huang B; Sun M; Su G; Zhou D; Wang G; Hao R; Wang N
Front Biosci (Landmark Ed); 2021 Oct; 26(10):789-798. PubMed ID: 34719206
[No Abstract] [Full Text] [Related]
17. Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication.
Chu J; Xing C; Du Y; Duan T; Liu S; Zhang P; Cheng C; Henley J; Liu X; Qian C; Yin B; Wang HY; Wang RF
Nat Metab; 2021 Nov; 3(11):1466-1475. PubMed ID: 34580494
[TBL] [Abstract][Full Text] [Related]
18. Novel Broad-Spectrum Antiviral Inhibitors Targeting Host Factors Essential for Replication of Pathogenic RNA Viruses.
Tampere M; Pettke A; Salata C; Wallner O; Koolmeister T; Cazares-Körner A; Visnes T; Hesselman MC; Kunold E; Wiita E; Kalderén C; Lightowler M; Jemth AS; Lehtiö J; Rosenquist Å; Warpman-Berglund U; Helleday T; Mirazimi A; Jafari R; Puumalainen MR
Viruses; 2020 Dec; 12(12):. PubMed ID: 33322045
[TBL] [Abstract][Full Text] [Related]
19. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.
Blaess M; Kaiser L; Sommerfeld O; Csuk R; Deigner HP
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670304
[TBL] [Abstract][Full Text] [Related]
20. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.
Bojkova D; Klann K; Koch B; Widera M; Krause D; Ciesek S; Cinatl J; Münch C
Nature; 2020 Jul; 583(7816):469-472. PubMed ID: 32408336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
